(function(){var loadHandler=window['sl_{21FEF8D7-4385-4DEB-B34B-7A4BB675EF9A}'];loadHandler&&loadHandler(11, '<div id="spr0_1587365c"><div id="spr1_1587365c" class="kern slide"><img id="img4_1587365c" src="data/img8.png" width="720px" height="540px" alt="" style="left:0px;top:0px;"/></div><div id="spr2_1587365c" class="kern slide"><img id="img0_1587365c" src="data/img17.png" width="721.48" height="46.226" alt="" style="left:-0.439px;top:493.774px;"/><img id="img1_1587365c" src="data/img1.png" width="721.48" height="100.8" alt="" style="left:-0.439px;"/><div id="spr3_1587365c" style="left:657.715px;top:502.143px;"><img id="img2_1587365c" src="data/img3.png" width="56" height="36" alt="CHRC logo_with text.psd" style="left:-0.105px;top:-0.177px;"/></div><div id="spr4_1587365c" style="left:28.702px;top:-3.551px;"><div style="width:0px;"><span id="txt0_1587365c" class="relpos" style="left:188.702px;top:5.458px;"> </span><span id="txt1_1587365c" class="relpos" data-width="295.294922" style="left:188.697px;top:9.189px;">ODYSSEY Outcomes</span></div><div style="width:0px;"><span id="txt2_1587365c" data-width="472.394531" style="left:104.447px;top:53.272px;">Primary Efficacy Endpoint: MACE</span></div></div><div id="spr5_1587365c" style="left:567.407px;top:147.918px;"><div style="width:0px;"><span id="txt3_1587365c" class="nokern" data-width="56.583984" style="left:7.2px;top:4.227px;">ARR* 1.6%</span></div></div><div id="spr6_1587365c" style="left:21.19px;top:473.978px;"><div style="width:0px;"><span id="txt4_1587365c" class="nokern" data-width="150.398438" style="left:7.2px;top:4.157px;">*Based on cumulative incidence</span></div></div><div id="spr7_1587365c" style="left:19.805px;top:508.807px;"><div style="width:0px;"><span id="txt5_1587365c" class="nokern relpos" data-width="45.140625" style="left:9.321px;top:6.217px;">Steg G. et al; </span><span id="txt6_1587365c" class="nokern relpos" data-width="489.001465" style="left:9.316px;top:6.217px;">On behalf of the ODYSSEY OUTCOMES Investigators and Committees - American College of Cardiology – 67th Scientific Sessions - March 10, 2018</span></div></div><div id="spr8_1587365c" style="left:19.805px;top:508.807px;"><div style="width:0px;"><span id="txt7_1587365c" class="nokern relpos" data-width="45.140625" style="left:7.2px;top:4.096px;">Steg G. et al; </span><span id="txt8_1587365c" class="nokern relpos" data-width="489.001465" style="left:7.195px;top:4.096px;">On behalf of the ODYSSEY OUTCOMES Investigators and Committees - American College of Cardiology – 67th Scientific Sessions - March 10, 2018</span></div></div><div id="spr9_1587365c" style="top:104.208px;"><div style="width:0px;"><span id="txt9_1587365c" class="nokern" data-width="584.695313" style="left:68.875px;top:3.209px;">MACE: CHD death, non-fatal MI, ischemic stroke, or  unstable angina requiring hospitalization</span></div></div><div id="spr10_1587365c" style="left:132.316px;top:134.354px;"><img id="img3_1587365c" src="data/img27.png" width="480" height="336" alt="chart-redraw-April9\'18-2.jpg" style="left:-0.158px;top:-0.177px;"/></div></div></div>');})();